U.S. Markets closed

DIAGNOS Announces Saudi FDA Filing for its CARA AI Platform

BROSSARD, Quebec, May 07, 2019 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today that it has started the marketing authorization filing process with the Saudi Food and Drug Authority (SFDA) for its CARA proprietary tool comprised of a telemedicine platform combined with automated detection algorithms based on Artificial Intelligence. The telemedicine platform as well as the associated algorithms will be part of the submission to the SFDA for approval.

“DIAGNOS has been present in the Middle East for many years and is fully committed to the region.  We have demonstrated to the local administration that our AI solution can help save lives.  After a lengthy successful pilot in Saudi Arabia with the local authorities, through our local partner, it is now time to move forward with the formal acceptance of the CARA Platform by the government.  Our local partner has played a very strategic role in the development of the potential business in Saudi Arabia and the gulf region”, said André Larente, CEO of DIAGNOS.

DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.

Additional information is available at www.diagnos.com and www.sedar.com

For further information about this press release, please contact:

Mr. André Larente, President
Tel: 450-678-8882 ext. 224

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.